In-vitro blood-brain barrier models for drug screening and permeation studies: an overview

References

• He Y, Yao Y, Tsirka SE, Cao Y. Cell-culture models of the blood–brain barrier. Stroke. 2014;45(8):2514–2526. doi:10.1161/STROKEAHA.114.00542724938839
   PubMed Web of Science ®Google Scholar
• Stern L, Gautier R II. Les Rapports Entre Le Liquide Céphalo-Rachidien Et Les éléments Nerveux De L’axe Cerebrospinal. Arch Int Physiol. 1922;17(4):391–448. doi:10.3109/13813452209146219
   Google Scholar
• Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol. 2004;75(3):388–397. doi:10.1189/jlb.030311414612429
   PubMed Web of Science ®Google Scholar
• Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood–brain barrier in drug discovery and development. Nat Rev Drug Discov. 2007;6(8):650–661. doi:10.1038/nrd236817667956
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood–brain barriers. Trends Immunol. 2012;33(12):579–589. doi:10.1016/j.it.2012.07.00422926201
   PubMed Web of Science ®Google Scholar
• Jouyban A, Soltani S. Blood brain barrier permeation. Toxic Drug Test. In: Bill Acree, Editor, Croatia: InTech. 2012;1:1–24.
   Google Scholar
• Nair M, Jayant RD, Kaushik A, Sagar V. Getting into the brain: potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev. 2016;103:202–217. doi:10.1016/j.addr.2016.02.00826944096
   PubMed Web of Science ®Google Scholar
• Abbott NJ Physiology of the blood–brain barrier and its consequences for drug transport to the brain. Paper presented at: International Congress Series; 2005
   Google Scholar
• Gajdács M. The concept of an ideal antibiotic: implications for drug design. Molecules. 2019;24(5):892. doi:10.3390/molecules24050892
   PubMed Web of Science ®Google Scholar
• Cardoso FL, Brites D, Brito MA. Looking at the blood–brain barrier: molecular anatomy and possible investigation approaches. Brain Res Rev. 2010;64(2):328–363. doi:10.1016/j.brainresrev.2010.05.00320685221
   PubMed Web of Science ®Google Scholar
• Prinz M, Mildner A. Microglia in the CNS: immigrants from another world. Glia. 2011;59(2):177–187. doi:10.1002/glia.2110421125659
   PubMed Web of Science ®Google Scholar
• Aday S, Cecchelli R, Hallier-Vanuxeem D, Dehouck M, Ferreira L. Stem cell-based human blood–brain barrier models for drug discovery and delivery. Trends Biotechnol. 2016;34(5):382–393. doi:10.1016/j.tibtech.2016.01.00126838094
   PubMed Web of Science ®Google Scholar
• Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16(1):1–13. doi:10.1016/j.nbd.2003.12.01615207256
   PubMed Web of Science ®Google Scholar
• Helms HC, Abbott NJ, Burek M, et al. In vitro models of the blood–brain barrier: an overview of commonly used brain endothelial cell culture models and guidelines for their use. J Cereb Blood Flow Metab. 2016;36(5):862–890. doi:10.1177/0271678X1663099126868179
   PubMed Web of Science ®Google Scholar
• Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2(1):86–98. doi:10.1602/neurorx.2.1.8615717060
   PubMedGoogle Scholar
• Löscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005;76(1):22–76. doi:10.1016/j.pneurobio.2005.04.00616011870
   PubMed Web of Science ®Google Scholar
• Kaushik A, Jayant RD, Bhardwaj V, Nair M. Personalized nanomedicine for CNS diseases. Drug Discov Today. 2018;23(5):1007–1015. doi:10.1016/j.drudis.2017.11.01029155026
   PubMed Web of Science ®Google Scholar
• Kaushik A, Jayant RD, Nair M. Nanomedicine for neuroHIV/AIDS Management. London, UK: Future Medicine Ltd; 2018.
   Google Scholar
• Kaushik A, Yndart A, Atluri V, et al. Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection. Sci Rep. 2019;9(1):3928. doi:10.1038/s41598-019-40222-430850620
   PubMed Web of Science ®Google Scholar
• Lee M, Jayant R. Penetration of the blood-brain barrier by peripheral neuropeptides: new approaches to enhancing transport and endogenous expression. Cell Tissue Res. 2019;375(1):287–293. doi:10.1007/s00441-018-2959-y30535799
   PubMed Web of Science ®Google Scholar
• Surnar B, Basu U, Banik B, et al. Nanotechnology-mediated crossing of two impermeable membranes to modulate the stars of the neurovascular unit for neuroprotection. Proc Natl Acad Sci. 2018;115(52):E12333–E12342. doi:10.1073/pnas.181642911530530697
   PubMed Web of Science ®Google Scholar
• Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx. 2005;2(4):554–571. doi:10.1602/neurorx.2.4.55416489365
   PubMedGoogle Scholar
• Teleanu D, Chircov C, Grumezescu A, Volceanov A, Teleanu R. Blood-brain delivery methods using nanotechnology. Pharmaceutics. 2018;10(4):269. doi:10.3390/pharmaceutics10040269
   PubMed Web of Science ®Google Scholar
• Czupalla CJ, Liebner S, Devraj K. In vitro models of the blood–brain barrier In:  Milner R. Editor. Cerebral Angiogenesis: Methods and Protocols; NY: Humana Press. 2014;1135:415–437.
   Google Scholar
• Garberg P, Ball M, Borg N, et al. In vitro models for the blood–brain barrier. Toxicol in Vitro. 2005;19(3):299–334. doi:10.1016/j.tiv.2004.06.01115713540
   PubMed Web of Science ®Google Scholar
• Wilhelm I, Fazakas C, Krizbai IA. In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Wars). 2011;71(1):113–128.21499332
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Deli MA, Kawaguchi H, et al. A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int. 2009;54(3):253–263. doi:10.1016/j.neuint.2008.12.00219111869
   PubMed Web of Science ®Google Scholar
• Lippmann ES, Al-Ahmad A, Palecek SP, Shusta EV. Modeling the blood–brain barrier using stem cell sources. Fluids Barriers CNS. 2013;10(1):2. doi:10.1186/2045-8118-10-223305164
   PubMedGoogle Scholar
• Daniels BP, Cruz-Orengo L, Pasieka TJ, et al. Immortalized human cerebral microvascular endothelial cells maintain the properties of primary cells in an in vitro model of immune migration across the blood brain barrier. J Neurosci Methods. 2013;212(1):173–179. doi:10.1016/j.jneumeth.2012.10.00123068604
   PubMed Web of Science ®Google Scholar
• Franke H, Galla H-J, Beuckmann CT. An improved low-permeability in vitro-model of the blood–brain barrier: transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain Res. 1999;818(1):65–71. doi:10.1016/s0006-8993(98)01282-79914438
   PubMed Web of Science ®Google Scholar
• Hurst R, Fritz I. Properties of an immortalised vascular endothelial/glioma cell co-culture model of the blood-brain barrier. J Cell Physiol. 1996;167(1):81–88. doi:10.1002/(SICI)1097-4652(199604)167:1<81::AID-JCP9>3.0.CO;2-88698844
   PubMed Web of Science ®Google Scholar
• Hori S, Ohtsuki S, Hosoya K, Nakashima E, Terasaki T. A pericyte‐derived angiopoietin‐1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie‐2 activation in vitro. J Neurochem. 2004;89(2):503–513. doi:10.1111/j.1471-4159.2004.02343.x15056293
   PubMed Web of Science ®Google Scholar
• Toimela T, Mäenpää H, Mannerström M, Tähti H. Development of an in vitro blood–brain barrier model—cytotoxicity of mercury and aluminum. Toxicol Appl Pharmacol. 2004;195(1):73–82. doi:10.1016/j.taap.2003.11.00214962507
   PubMed Web of Science ®Google Scholar
• Armulik A, Genové G, Mäe M, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468(7323):557–561. doi:10.1038/nature0952220944627
   PubMed Web of Science ®Google Scholar
• Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature. 2010;468(7323):562–566. doi:10.1038/nature0951320944625
   PubMed Web of Science ®Google Scholar
• Atluri VSR, Jayant RD, Pilakka-Kanthikeel S, et al. Development of TIMP1 magnetic nanoformulation for regulation of synaptic plasticity in HIV-1 infection. Int J Nanomedicine. 2016;11:4287. doi:10.2147/IJN.S10832927621622
   PubMed Web of Science ®Google Scholar
• Jayant R. Layer-by-Layer (LbL) assembly of anti HIV drug for sustained release to brain using magnetic nanoparticle. Paper presented at: Journal of Neuroimmune Pharmacology; 2014.
   Google Scholar
• Jayant R, Nair M. Nanotechnology for the treatment of neuroAIDS. J Nanomed Res. 2016;3(1):00047. doi:10.15406/jnmr.2016.03.00047
   Google Scholar
• Jayant R, Nair M. Role of biosensing technology for neuroAIDS management. J Biosens Bioelectron. 2016;7(1).
   PubMedGoogle Scholar
• Jayant RD, Madhavan N Materials and methods for sustained release of active compounds. US Patent App. 15/082,611. 2016.
   Google Scholar
• Kaushik A, Jayant RD, Nair M. Advancements in nano-enabled therapeutics for neuroHIv management. Int J Nanomedicine. 2016;11:4317. doi:10.2147/IJN.S10994327621624
   PubMed Web of Science ®Google Scholar
• Tomitaka A, Arami H, Raymond A, et al. Development of magneto-plasmonic nanoparticles for multimodal image-guided therapy to the brain. Nanoscale. 2017;9(2):764–773. doi:10.1039/c6nr07520g27976764
   PubMed Web of Science ®Google Scholar
• Nair M, Guduru R, Liang P, Hong J, Sagar V, Khizroev S. Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers. Nat Commun. 2013;4:1707. doi:10.1038/ncomms271723591874
   PubMed Web of Science ®Google Scholar
• Pilakka-Kanthikeel S, Atluri VSR, Sagar V, Saxena SK, Nair M. Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study. PLoS One. 2013;8(4):e62241. doi:10.1371/journal.pone.006224123653680
   PubMed Web of Science ®Google Scholar
• Ding H, Sagar V, Agudelo M, et al. Enhanced blood–brain barrier transmigration using a novel transferrin embedded fluorescent magneto-liposome nanoformulation. Nanotechnology. 2014;25(5):055101. doi:10.1088/0957-4484/25/5/05510124406534
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Deli MA, Nakao S, et al. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol. 2007;27(6):687–694. doi:10.1007/s10571-007-9195-417823866
   PubMed Web of Science ®Google Scholar
• Siddharthan V, Kim YV, Liu S, Kim KS. Human astrocytes/astrocyte-conditioned medium and shear stress enhance the barrier properties of human brain microvascular endothelial cells. Brain Res. 2007;1147:39–50. doi:10.1016/j.brainres.2007.02.02917368578
   PubMed Web of Science ®Google Scholar
• Tarbell JM. Shear stress and the endothelial transport barrier. Cardiovasc Res. 2010;87(2):320–330. doi:10.1093/cvr/cvq14620543206
   PubMed Web of Science ®Google Scholar
• Bussolari SR, Dewey CF Jr, Gimbrone MA Jr. Apparatus for subjecting living cells to fluid shear stress. Rev Sci Instrum. 1982;53(12):1851–1854. doi:10.1063/1.11369097156852
   PubMed Web of Science ®Google Scholar
• Naik P, Cucullo L. In vitro blood–brain barrier models: current and perspective technologies. J Pharm Sci. 2012;101(4):1337–1354. doi:10.1002/jps.2302222213383
   PubMed Web of Science ®Google Scholar
• Koutsiaris AG, Tachmitzi SV, Batis N, et al. Volume flow and wall shear stress quantification in the human conjunctival capillaries and post-capillary venules in vivo. Biorheology. 2007;44(5–6):375–386.18401076
   PubMed Web of Science ®Google Scholar
• Cucullo L, Hossain M, Rapp E, Manders T, Marchi N, Janigro D. Development of a humanized in vitro blood–brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia. 2007;48(3):505–516. doi:10.1111/j.1528-1167.2006.00960.x17326793
   PubMed Web of Science ®Google Scholar
• Cucullo L, Marchi N, Hossain M, Janigro D. A dynamic in vitro BBB model for the study of immune cell trafficking into the central nervous system. J Cereb Blood Flow Metab. 2011;31(2):767–777. doi:10.1038/jcbfm.2010.16220842162
   PubMed Web of Science ®Google Scholar
• Booth R, Kim H. Characterization of a microfluidic in vitro model of the blood-brain barrier (μBBB). Lab Chip. 2012;12(10):1784–1792. doi:10.1039/c2lc40094d22422217
   PubMed Web of Science ®Google Scholar
• Prabhakarpandian B, Shen M-C, Nichols JB, et al. SyM-BBB: a microfluidic blood brain barrier model. Lab Chip. 2013;13(6):1093–1101. doi:10.1039/c2lc41208j23344641
   PubMed Web of Science ®Google Scholar
• Booth R, Kim H A multi-layered microfluidic device for in vitro bloodbrain barrier permeability studies. Paper presented at: International Conference on Miniaturized Systems for Chemistry and Life Sciences; 2011.
   Google Scholar
• Kokubu Y, Yamaguchi T, Kawabata K. In vitro model of cerebral ischemia by using brain microvascular endothelial cells derived from human induced pluripotent stem cells. Biochem Biophys Res Commun. 2017;486(2):577–583. doi:10.1016/j.bbrc.2017.03.09228336435
   PubMed Web of Science ®Google Scholar
• Page S, Patel R, Raut S, Al-Ahmad A. Neurological diseases at the blood-brain barrier: stemming new scientific paradigms using patient-derived induced pluripotent cells. Biochim Biophys Acta Mol Basis Dis. 2018. doi:10.1016/j.bbadis.2018.12.009
   PubMed Web of Science ®Google Scholar
• Li Y, Sun X, Liu H, et al. Development of human in vitro brain-blood barrier model from induced pluripotent stem cell-derived endothelial cells to predict the in vivo permeability of drugs. Neurosci Bull. 2019:1–15. doi:10.1007/s12264-019-00384-730659525
   PubMed Web of Science ®Google Scholar
• Hollmann EK, Bailey AK, Potharazu AV, Neely MD, Bowman AB, Lippmann ES. Accelerated differentiation of human induced pluripotent stem cells to blood-brain barrier endothelial cells. Fluids Barriers CNS. 2017;14(1):9. doi:10.1186/s12987-017-0059-028407791
   PubMed Web of Science ®Google Scholar
• Canfield SG, Stebbins MJ, Morales BS, et al. An isogenic blood-brain barrier model comprising brain endothelial cells, astrocytes, and neurons derived from human induced pluripotent stem cells. J Neurochem. 2017;140(6):874–888. doi:10.1111/jnc.1392327935037
   PubMed Web of Science ®Google Scholar
• Vastag M, Keseru GM. Current in vitro and in silico models of blood-brain barrier penetration: a practical view. Curr Opin Drug Discov Devel. 2009;12(1):115–124.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Prediction of blood–brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov Today Technol. 2004;1(4):407–416. doi:10.1016/j.ddtec.2004.11.01424981621
   PubMedGoogle Scholar
• Goodwin JT, Clark DE. In silico predictions of blood-brain barrier penetration: considerations to “Keep in mind”. J Pharmacol Exp Ther. 2005;315(2):477–483. doi:10.1124/jpet.104.07570515919767
   PubMed Web of Science ®Google Scholar
• Mensch J, Oyarzabal J, Mackie C, Augustijns P. In vivo, in vitro and in silico methods for small molecule transfer across the BBB. J Pharm Sci. 2009;98(12):4429–4468. doi:10.1002/jps.2174519408294
   PubMed Web of Science ®Google Scholar
• Deli MA. Drug Transport and the Blood-brain Barrier. Solubility, Delivery, and ADME Problems of Drugs and Drug-Candidates. Washington: Bentham Science Publ Ltd; 2011:144–165.
   Google Scholar
• Bendels S, Kansy M, Wagner B, Huwyler J. In silico prediction of brain and CSF permeation of small molecules using PLS regression models. Eur J Med Chem. 2008;43(8):1581–1592. doi:10.1016/j.ejmech.2007.11.01118206268
   PubMed Web of Science ®Google Scholar
• Garg P, Verma J, Roy N. In silico modeling for blood—brain barrier permeability predictions. In: Ehrhardt C, Kim KJ, Editors Drug Absorption Studies. Springer; 2008;VII:510–556.
   Google Scholar
• Konovalov DA, Coomans D, Deconinck E, Vander Heyden Y. Benchmarking of QSAR models for blood-brain barrier permeation. J Chem Inf Model. 2007;47(4):1648–1656. doi:10.1021/ci700100f17602606
   PubMed Web of Science ®Google Scholar
• Liu X, Tu M, Kelly RS, Chen C, Smith BJ. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos. 2004;32(1):132–139. doi:10.1124/dmd.32.1.13214709630
   PubMed Web of Science ®Google Scholar
• Abraham MH. The factors that influence permeation across the blood–brain barrier. Eur J Med Chem. 2004;39(3):235–240. doi:10.1016/j.ejmech.2003.12.00415051171
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1–3):3–25. doi:10.1016/S0169-409X(96)00423-1
   Web of Science ®Google Scholar
• Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1(4):337–341. doi:10.1016/j.ddtec.2004.11.00724981612
   PubMedGoogle Scholar
• Glave W, Hansch C. Relationship between lipophilic character and anesthetic activity. J Pharm Sci. 1972;61(4):589–591. doi:10.1002/jps.26006104205014317
   PubMed Web of Science ®Google Scholar
• Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2(4):541–553. doi:10.1602/neurorx.2.4.54116489364
   PubMedGoogle Scholar
• Hitchcock SA. Blood–brain barrier permeability considerations for CNS-targeted compound library design. Curr Opin Chem Biol. 2008;12(3):318–323. doi:10.1016/j.cbpa.2008.03.01918435937
   PubMed Web of Science ®Google Scholar
• Levin VA, Dolginow D, Landahl HD, Yorke C, Csejtey J. Relationship of octanol/water partition coefficient and molecular weight to cellular permeability and partitioning in S49 lymphoma cells. Pharm Res. 1984;1(6):259–266. doi:10.1023/A:101639390212324277359
   PubMed Web of Science ®Google Scholar
• Young RC, Mitchell RC, Brown TH, et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem. 1988;31(3):656–671. doi:10.1021/jm00398a0282894467
   PubMed Web of Science ®Google Scholar
• Abraham MH, Takács‐Novák K, Mitchell RC. On the partition of ampholytes: application to blood–brain distribution. J Pharm Sci. 1997;86(3):310–315. doi:10.1021/js960328j9050798
   PubMed Web of Science ®Google Scholar
• Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther. 2008;325(2):349–356. doi:10.1124/jpet.107.13029418203948
   PubMed Web of Science ®Google Scholar
• Sakolish CM, Esch MB, Hickman JJ, Shuler ML, Mahler GJ. Modeling barrier tissues in vitro: methods, achievements, and challenges. EBioMedicine. 2016;5:30–39. doi:10.1016/j.ebiom.2016.02.02327077109
   PubMed Web of Science ®Google Scholar
• Veszelka S, Kittel Á, Deli MA. Tools of Modelling Blood–brain Barrier Penetrability. Solubility, Delivery and ADME Problems of Drugs and Drug Candidates. Washington: Bentham Science; 2011:166–188.
   Google Scholar
• Tornabene E, Brodin B. Stroke and drug delivery—in vitro models of the ischemic blood-brain barrier. J Pharm Sci. 2016;105(2):398–405. doi:10.1016/j.xphs.2015.11.04126869407
   PubMed Web of Science ®Google Scholar
• Wang JD, Khafagy E-S, Khanafer K, Takayama S, ElSayed MEH. Organization of endothelial cells, pericytes, and astrocytes into a 3D microfluidic in vitro model of the blood–brain barrier. Mol Pharm. 2016;13(3):895–906. doi:10.1021/acs.molpharmaceut.5b0080526751280
   PubMed Web of Science ®Google Scholar